On December 10, 2020, Aytu BioScience, Inc. and Neutron Acquisition Sub, Inc. entered into an Agreement and Plan of Merger with Neos Therapeutics, Inc. The Merger Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Neos, with Neos surviving as a wholly owned subsidiary of Aytu. On March 19, 2021, pursuant to the Merger Agreement, Ketan Mehta resigned from Aytu’s board of directors (the “Board”). On March 19, 2021, pursuant to the Merger Agreement, the Board appointed Gerald McLaughlin and Beth Hecht, directors of Neos, as directors of Aytu.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.